Evogliptin (DA-1229) is a DPP4 inhibitor with oral activity. Evogliptin has significant and lasting hypoglycemic effect in mouse model. Evogliptin inhibits the production of the fibrosis and inflammatory in hepatocytes signals by inducing autophagy. Evogliptin can be used to study type 2 diabetes, chronic liver inflammation, osteoporosis and renal impairment.

Evogliptin (2.49 mM; 12 h) effectively suppresses mDPP4 (membrane DPP4) activity without impacting cytokine levels or cell viability in PWM-induced H9 Th1 cells, demonstrating selective inhibition of the enzyme. Furthermore, it mitigates inflammatory and fibrotic responses by promoting autophagy in ATG7 f/f -Cre+ mouse primary hepatocytes. This specificity and dual functionality underscore its therapeutic potential, as evidenced by cell viability assays in dose-dependent evaluations.

Evogliptin, administered at doses of 100 and 300 mg/kg through animal feed once daily for ten weeks, has demonstrated antidiabetic effects in HFD/STZ mice by improving glucose intolerance and insulin resistance. This study involved male ICR mice, modeling HFD/STZ-induced diabetes, where evogliptin significantly reduced blood glucose levels starting from the second week, a reduction that was sustained throughout the 10-week period, especially at the 300 mg/kg dosage. Additionally, a significant decrease in HbA1c levels was observed at the 300 mg/kg dose, along with a dose-dependent reduction in 6-hour fasted blood glucose levels, showcasing its potential in diabetes management.